Home

CFAR

Personnel

Questions

Mission

Glossary

Clinical Trials

Consents

Feedback

CAB

Links

CLINICAL TRIAL CONSENTS:

ACTG Studies

ACTU Newletter 02/2012

ACTU Study Flow 11/2012

CFAR Query Request Form

CHOP Blood Draw Study IC V1 12/17/09

Cryopreservation IC V9 1/25/10 *EFFECTIVE 9/4/12

A5001 HIPPA V4 IC V13 3/5/12 *EFFECTIVE 2/28/13

A5128 V3 IC V7 1/28/13 *EFFECTIVE 2/11/13

A5251 V2 IC V3 3/5/12 *EFFECTIVE 7/25/12

A5257HIPPA V2 IC V10 3/8/12 *EFFECTIVE 11/5/12

A5257 V2 Pregnancy IC V3 1/14/10

A5258 V2 IC V5 9/20/12 *EFFECTIVE 11/8/12

A5258 V2Pregnancy IC V3 9/20/12 *EFFECTIVE 11/8/12

A5275 V1 IC V6 12/3/12 *EFFECTIVE 3/7/13

A5276s V1 A5001 substudy IC V3 3/5/12 *EFFECTIVE 2/28/13

A5280 V1 IC V6 11/7/12 *EFFECTIVE 12/20/12

A5281 V3 IC V3 3/16/12 *EFFECTIVE 5/14/12

A5294 V2 IC V5 12/4/12 *EFFECTIVE 12/20/12

A5298 V2 IC V4 10/11/12 *EFFECTIVE 12/6/12

A5303 V1 IC V6 10/11/12 *EFFECTIVE 10/19/12

HPTN 069/A5305 V3 IC V5 3/28/13 *EFFECTIVE 5/20/13

A5308 V1 IC V3 3/14/13 *EFFECTIVE 3/18/13

Leukapheresis IC V3 4/11/13 *EFFECTIVE 4/17/13

Promise V2 IC V6 3/28/13 *EFFECTIVE 5/2/13

Promise V2Pregnancy IC V4 5/9/13 *EFFECTIVE 5/15/13

Promise V2 stored specimen IC V3 11/5/12 *EFFECTIVE 12/20/12

Industry Studies

Adaptimmune Arm 1&2 - Arm 3&4 *EFFECTIVE 10/12/12

BMS AI467003 IC V4 6/21/12 / PGX IC V2 3/21/12 *EFFECTIVE 3/7/13

Emend III IC V6 9/19/12 *EFFECTIVE 4/8/13

Gilead US183-0145 IC V10 1/15/13 *EFFECTIVE 2/14/13

Gilead US216-0114 IC4 1/7/13 *EFFECTIVE 2/25/13

Gilead US216-0130 IC6 2/18/13 *EFFECTIVE 3/7/13

Gilead US236-0102 IC6 2/4/13 *EFFECTIVE 4/4/13

Gilead US236-0115 IC6 2/4/13 *EFFECTIVE 3/12/13

Gilead US248-0122 IC3 2/20/13 *EFFECTIVE 3/7/13

Gilead US248-0123 IC3 1/30/13 *EFFECTIVE 3/7/13

Gilead US264-0106 IC6 3/19/12 *EFFECTIVE 5/29/12

Gilead US264-0110 IC7 2/6/13 *EFFECTIVE 3/27/13

Gilead US292-0104 IC3 3/4/13 *EFFECTIVE 3/25/13

Gilead US292-0111 IC2 3/3/13 *EFFECTIVE 5/6/13

Gilead US334-0123 TX Naive 2 &3 IC4 8/30/12 *EFFECTIVE 10/8/12

Gilead US334-0123 TX Exp 2&3, Naive 1 IC2 8/30/12 *EFFECTIVE 10/8/12

Gilead US334-0123 PGx IC3 8/30/12 *EFFECTIVE 10/10/12

GSK HIV011 IC V3 6/2/2012 *EFFECTIVE 2/4/13

GSK Flamingo - ING114915 IC V3 3/18/13 *EFFECTIVE 4/10/13

IRC001 Pheresis IC V8 12/4/12 *EFFECTIVE 12/17/12

IRC002 IC V6 9/13/12 *EFFECTIVE 9/26/12

IRC004 V4 IC V4 10/22/12 *EFFECTIVE 10/31/12

Jean Boyer Venipuncture Study IC V5 5/24/12 *EFFECTIVE 3/18/13

LoRe Hep C and Bone Disease V2 4/6/10 *EFFECTIVE 8/10/12

Merck 1439-007 IC V3 1/14/13 *EFFECTIVE 3/14/13

Merck 1439 Future Biomedical Research IC V2 1/14/13 *EFFECTIVE 3/14/13

Pfizer Poem A4001067 IC V5 3/21/12 *EFFECTIVE 2/28/13

Sangamo V7 Cohort 1 11/17/09 / Cohort 2 5/3/10 / Cohort 3 11/17/09

Sangamo LTFU V3 1/23/12 *EFFECTIVE 2/5/13

Statin HAND Study HIPPA V1.1 IC 4/18/12 *EFFECTIVE 2/18/13

Tobira 625-2-202 IC V5 4/18/12 *EFFECTIVE 5/15/12

Vertex VX11-950-0115 V3 IC V4 2/6/13 *EFFECTIVE 3/18/13

Vertex VX11-950-0115 V3 DNA IC V2 3/21/12 *EFFECTIVE 6/27/12

Virxsys/Adapt LTFU 3/30/12 - *EFFECTIVE 5/3/12